Antibody-Drug Conjugates (ADCs) represent the biggest breakthrough in the treatment of cancer since the advent of chemotherapy. The unparalleled potential of ADCs to significantly benefit patients has rallied every major pharma to the field and huge investments are being made to progress more of these game changing therapies.
ADC drug developers, service and solution providers have been working with World ADC for the past 9 years to access the latest insight into scientific breakthroughs and establish meaningful and mutually beneficially collaborations that can help them to accelerate progress.
World ADC consistently provides valuable intelligence, solutions and platforms whether that be through market leading events, webinars or relevant industry content.
As a result, World ADC is first point of call for organisations looking to gain a competitive edge in the ADC space.